---
document_datetime: 2025-11-23 07:58:28
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/azacitidine-celgene.html
document_name: azacitidine-celgene.html
version: success
processing_time: 0.0994396
conversion_datetime: 2025-12-25 10:58:14.054706
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Azacitidine Celgene

[RSS](/en/individual-human-medicine.xml/67232)

##### Withdrawn

This medicine's authorisation has been withdrawn

azacitidine

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Azacitidine Celgene](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 19 May 2021, the European Commission withdrew the marketing authorisation for Azacitidine Celgene (SRD) (azacitidine) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Celgene Europe BV, which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Azacitidine Celgene was granted marketing authorisation in the EU on 2 August 2019 for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:

- intermediate-2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
- chronic myelomonocytic leukaemia (CMML) with 10-29 % marrow blasts without myeloproliferative disorder,
- acute myeloid leukaemia (AML) with 20-30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,
- AML with &gt;30% marrow blasts according to the WHO classification.

The marketing authorisation was initially valid for a 5-year period.

Azacitidine Celgene is identical to Vidaza, which is authorised in the EU for the same indications as Azacitidine Celgene. The marketing authorisation holder will maintain the marketing authorisation for Vidaza.

The European Public Assessment Report (EPAR) for Azacitidine Celgene is updated to indicate that the marketing authorisation is no longer valid.

Azacitidine Celgene : EPAR - Medicine overview

Reference Number: EMA/384352/2019

English (EN) (664.65 KB - PDF)

**First published:** 14/08/2019

**Last updated:** 04/08/2021

[View](/en/documents/overview/azacitidine-celgene-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-474)

български (BG) (759.74 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/bg/documents/overview/azacitidine-celgene-epar-medicine-overview_bg.pdf)

español (ES) (663.79 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/es/documents/overview/azacitidine-celgene-epar-medicine-overview_es.pdf)

čeština (CS) (742.02 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/cs/documents/overview/azacitidine-celgene-epar-medicine-overview_cs.pdf)

dansk (DA) (613.46 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/da/documents/overview/azacitidine-celgene-epar-medicine-overview_da.pdf)

Deutsch (DE) (664.92 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/de/documents/overview/azacitidine-celgene-epar-medicine-overview_de.pdf)

eesti keel (ET) (662.32 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/et/documents/overview/azacitidine-celgene-epar-medicine-overview_et.pdf)

ελληνικά (EL) (772.36 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/el/documents/overview/azacitidine-celgene-epar-medicine-overview_el.pdf)

français (FR) (664.57 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/fr/documents/overview/azacitidine-celgene-epar-medicine-overview_fr.pdf)

hrvatski (HR) (687.97 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/hr/documents/overview/azacitidine-celgene-epar-medicine-overview_hr.pdf)

italiano (IT) (661.86 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/it/documents/overview/azacitidine-celgene-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (747.91 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/lv/documents/overview/azacitidine-celgene-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (689.92 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/lt/documents/overview/azacitidine-celgene-epar-medicine-overview_lt.pdf)

magyar (HU) (735.9 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/hu/documents/overview/azacitidine-celgene-epar-medicine-overview_hu.pdf)

Malti (MT) (748.95 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/mt/documents/overview/azacitidine-celgene-epar-medicine-overview_mt.pdf)

Nederlands (NL) (662.38 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/nl/documents/overview/azacitidine-celgene-epar-medicine-overview_nl.pdf)

polski (PL) (736.99 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/pl/documents/overview/azacitidine-celgene-epar-medicine-overview_pl.pdf)

português (PT) (663.89 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/pt/documents/overview/azacitidine-celgene-epar-medicine-overview_pt.pdf)

română (RO) (695.1 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/ro/documents/overview/azacitidine-celgene-epar-medicine-overview_ro.pdf)

slovenčina (SK) (740.25 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/sk/documents/overview/azacitidine-celgene-epar-medicine-overview_sk.pdf)

slovenščina (SL) (733.35 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/sl/documents/overview/azacitidine-celgene-epar-medicine-overview_sl.pdf)

Suomi (FI) (661.01 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/fi/documents/overview/azacitidine-celgene-epar-medicine-overview_fi.pdf)

svenska (SV) (663.03 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/sv/documents/overview/azacitidine-celgene-epar-medicine-overview_sv.pdf)

Azacitidine Celgene : EPAR - Risk-management-plan summary

English (EN) (709.48 KB - PDF)

**First published:** 14/08/2019

**Last updated:** 04/08/2021

[View](/en/documents/rmp-summary/azacitidine-celgene-epar-risk-management-plan-summary_en.pdf)

## Product information

Azacitidine Celgene : EPAR - Product information

English (EN) (1.2 MB - PDF)

**First published:** 14/08/2019

**Last updated:** 04/08/2021

[View](/en/documents/product-information/azacitidine-celgene-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-326)

български (BG) (2.17 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/bg/documents/product-information/azacitidine-celgene-epar-product-information_bg.pdf)

español (ES) (1.2 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/es/documents/product-information/azacitidine-celgene-epar-product-information_es.pdf)

čeština (CS) (1.85 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/cs/documents/product-information/azacitidine-celgene-epar-product-information_cs.pdf)

dansk (DA) (1.19 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/da/documents/product-information/azacitidine-celgene-epar-product-information_da.pdf)

Deutsch (DE) (1.26 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/de/documents/product-information/azacitidine-celgene-epar-product-information_de.pdf)

eesti keel (ET) (1.23 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/et/documents/product-information/azacitidine-celgene-epar-product-information_et.pdf)

ελληνικά (EL) (1.91 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/el/documents/product-information/azacitidine-celgene-epar-product-information_el.pdf)

français (FR) (1.27 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/fr/documents/product-information/azacitidine-celgene-epar-product-information_fr.pdf)

hrvatski (HR) (1.27 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/hr/documents/product-information/azacitidine-celgene-epar-product-information_hr.pdf)

íslenska (IS) (1.23 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/is/documents/product-information/azacitidine-celgene-epar-product-information_is.pdf)

italiano (IT) (1.22 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/it/documents/product-information/azacitidine-celgene-epar-product-information_it.pdf)

latviešu valoda (LV) (1.96 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/lv/documents/product-information/azacitidine-celgene-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.32 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/lt/documents/product-information/azacitidine-celgene-epar-product-information_lt.pdf)

magyar (HU) (1.83 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/hu/documents/product-information/azacitidine-celgene-epar-product-information_hu.pdf)

Malti (MT) (1.98 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/mt/documents/product-information/azacitidine-celgene-epar-product-information_mt.pdf)

Nederlands (NL) (1.23 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/nl/documents/product-information/azacitidine-celgene-epar-product-information_nl.pdf)

norsk (NO) (1005.19 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/no/documents/product-information/azacitidine-celgene-epar-product-information_no.pdf)

polski (PL) (1.9 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/pl/documents/product-information/azacitidine-celgene-epar-product-information_pl.pdf)

português (PT) (435.74 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/pt/documents/product-information/azacitidine-celgene-epar-product-information_pt.pdf)

română (RO) (1.34 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/ro/documents/product-information/azacitidine-celgene-epar-product-information_ro.pdf)

slovenčina (SK) (1.91 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/sk/documents/product-information/azacitidine-celgene-epar-product-information_sk.pdf)

slovenščina (SL) (1.83 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/sl/documents/product-information/azacitidine-celgene-epar-product-information_sl.pdf)

Suomi (FI) (1.2 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/fi/documents/product-information/azacitidine-celgene-epar-product-information_fi.pdf)

svenska (SV) (1.21 MB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/sv/documents/product-information/azacitidine-celgene-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** WITHDRAWAL 21/05/2021

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Azacitidine Celgene : EPAR - All authorised presentations

English (EN) (594.29 KB - PDF)

**First published:** 14/08/2019

**Last updated:** 04/08/2021

[View](/en/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-854)

български (BG) (666.54 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/bg/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_bg.pdf)

español (ES) (636.01 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/es/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_es.pdf)

čeština (CS) (666.5 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/cs/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (658.23 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/da/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (644.69 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/de/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (633.49 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/et/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (663.78 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/el/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_el.pdf)

français (FR) (637.95 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/fr/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (634.97 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/hr/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (638.38 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/is/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_is.pdf)

italiano (IT) (635.86 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/it/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (657.93 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/lv/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (637.01 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/lt/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (653.48 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/hu/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (657.82 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/mt/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (635.42 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/nl/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (637.91 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/no/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_no.pdf)

polski (PL) (656.98 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/pl/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_pl.pdf)

português (PT) (637.04 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/pt/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_pt.pdf)

română (RO) (639.73 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/ro/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (656.6 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/sk/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (652.52 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/sl/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (633.48 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/fi/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (638.06 KB - PDF)

**First published:**

14/08/2019

**Last updated:**

04/08/2021

[View](/sv/documents/all-authorised-presentations/azacitidine-celgene-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Azacitidine Celgene Active substance azacitidine International non-proprietary name (INN) or common name azacitidine Therapeutic area (MeSH)

- Myelodysplastic Syndromes
- Leukemia, Myelomonocytic, Chronic
- Leukemia, Myeloid, Acute

Anatomical therapeutic chemical (ATC) code L01BC07

### Pharmacotherapeutic group

Antineoplastic agents

### Therapeutic indication

Azacitidine Celgene is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (HSCT) with:

- intermediate 2 and high-risk myelodysplastic syndromes (MDS) according to the International Prognostic Scoring System (IPSS),
- chronic myelomonocytic leukaemia (CMML) with 10 29 % marrow blasts without myeloproliferative disorder,
- acute myeloid leukaemia (AML) with 20 30 % blasts and multi-lineage dysplasia, according to World Health Organisation (WHO) classification,
- AML with &gt;30% marrow blasts according to the WHO classification.

## Authorisation details

EMA product number EMEA/H/C/005300 Marketing authorisation holder

Celgene Europe BV

Winthontlaan 6 N

Opinion adopted 27/06/2019 Marketing authorisation issued 02/08/2019 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Azacitidine Celgene : EPAR - Procedural steps taken and scientific information after the authorisation

English (EN) (713.23 KB - PDF)

**First published:** 24/06/2021

**Last updated:** 04/08/2021

[View](/en/documents/procedural-steps-after/azacitidine-celgene-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Azacitidine Celgene : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/445484/2019

English (EN) (816.42 KB - PDF)

**First published:** 14/08/2019

**Last updated:** 04/08/2021

[View](/en/documents/assessment-report/azacitidine-celgene-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Azacitidine Celgene

Adopted

Reference Number: EMA/CHMP/332005/2019

English (EN) (631.69 KB - PDF)

**First published:** 28/06/2019

**Last updated:** 04/08/2021

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-azacitidine-celgene_en.pdf)

#### News on Azacitidine Celgene

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 24-27 June 2019](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-24-27-june-2019) 28/06/2019

**This page was last updated on** 04/08/2021

## Share this page

[Back to top](#main-content)